These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 12470794)

  • 1. Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants.
    Lemere CA; Spooner ET; Leverone JF; Mori C; Clements JD
    Neurobiol Aging; 2002; 23(6):991-1000. PubMed ID: 12470794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of the humoral and cellular immune response in Abeta immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT(R192G).
    Maier M; Seabrook TJ; Lemere CA
    Vaccine; 2005 Oct; 23(44):5149-59. PubMed ID: 16054274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response.
    Maier M; Seabrook TJ; Lazo ND; Jiang L; Das P; Janus C; Lemere CA
    J Neurosci; 2006 May; 26(18):4717-28. PubMed ID: 16672644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abeta1-15 is less immunogenic than Abeta1-40/42 for intranasal immunization of wild-type mice but may be effective for "boosting".
    Leverone JF; Spooner ET; Lehman HK; Clements JD; Lemere CA
    Vaccine; 2003 May; 21(17-18):2197-206. PubMed ID: 12706711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mucosal adjuvanticity of two nontoxic mutants of Escherichia coli heat-labile enterotoxin varies with immunization routes.
    Park EJ; Chang JH; Kim JS; Yum JS; Chung SI
    Exp Mol Med; 2000 Jun; 32(2):72-8. PubMed ID: 10926118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developing novel immunogens for a safe and effective Alzheimer's disease vaccine.
    Lemere CA
    Prog Brain Res; 2009; 175():83-93. PubMed ID: 19660650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of the mucosal adjuvanticity of the type II heat-labile enterotoxins LT-IIa and LT-IIb.
    Martin M; Metzger DJ; Michalek SM; Connell TD; Russell MW
    Infect Immun; 2000 Jan; 68(1):281-7. PubMed ID: 10603399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of mutant Escherichia coli heat-labile enterotoxin (LT H44A) as an adjuvant for nasal influenza vaccine.
    Hagiwar Y; Tsuji T; Iwasaki T; Kadowaki S; Asanuma H; Chen Z; Komase K; Suzuki Y; Aizawa C; Kurata T; Tamura S
    Vaccine; 2001 Feb; 19(15-16):2071-9. PubMed ID: 11228379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of intranasal immunization with HIV-gp160 and an HIV-1 env CTL epitope peptide (E7) in combination with the mucosal adjuvant LT(R192G).
    Morris CB; Cheng E; Thanawastien A; Cárdenas-Freytag L; Clements JD
    Vaccine; 2000 Mar; 18(18):1944-51. PubMed ID: 10699345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection.
    Tumpey TM; Renshaw M; Clements JD; Katz JM
    J Virol; 2001 Jun; 75(11):5141-50. PubMed ID: 11333895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers.
    Stephenson I; Zambon MC; Rudin A; Colegate A; Podda A; Bugarini R; Del Giudice G; Minutello A; Bonnington S; Holmgren J; Mills KH; Nicholson KG
    J Virol; 2006 May; 80(10):4962-70. PubMed ID: 16641287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the reactogenicity, adjuvanticity and antigenicity of LT(R192G) and LT(R192G/L211A) by intradermal immunization in mice.
    Maciel M; Smith M; Poole ST; Laird RM; Rollenhagen JE; Kaminski RW; Wenzel H; Bourgeois AL; Savarino SJ
    PLoS One; 2019; 14(11):e0224073. PubMed ID: 31682624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeras of labile toxin one and cholera toxin retain mucosal adjuvanticity and direct Th cell subsets via their B subunit.
    Boyaka PN; Ohmura M; Fujihashi K; Koga T; Yamamoto M; Kweon MN; Takeda Y; Jackson RJ; Kiyono H; Yuki Y; McGhee JR
    J Immunol; 2003 Jan; 170(1):454-62. PubMed ID: 12496431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease.
    Kim HD; Jin JJ; Maxwell JA; Fukuchi K
    Immunol Lett; 2007 Sep; 112(1):30-8. PubMed ID: 17686533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch.
    Ghochikyan A; Mkrtichyan M; Petrushina I; Movsesyan N; Karapetyan A; Cribbs DH; Agadjanyan MG
    Vaccine; 2006 Mar; 24(13):2275-82. PubMed ID: 16368167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunostimulant patches containing Escherichia coli LT enhance immune responses to DNA- and recombinant protein-based Alzheimer's disease vaccines.
    Davtyan H; Ghochikyan A; Hovakimyan A; Petrushina I; Yu J; Flyer D; Madsen PJ; Pedersen LO; Cribbs DH; Agadjanyan MG
    J Neuroimmunol; 2014 Mar; 268(1-2):50-7. PubMed ID: 24507620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant.
    Choi AH; McNeal MM; Flint JA; Basu M; Lycke NY; Clements JD; Bean JA; Davis HL; McCluskie MJ; VanCott JL; Ward RL
    Vaccine; 2002 Mar; 20(13-14):1733-40. PubMed ID: 11906760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The New World primate, Aotus nancymae, as a model for examining the immunogenicity of a prototype enterotoxigenic Escherichia coli subunit vaccine.
    Jones FR; Hall ER; Tribble D; Savarino SJ; Cassels FJ; Porter C; Meza R; Nunez G; Espinoza N; Salazar M; Luckett R; Scott D
    Vaccine; 2006 May; 24(18):3786-92. PubMed ID: 16343702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Abeta immunogens: is shorter better?
    Lemere CA; Maier M; Peng Y; Jiang L; Seabrook TJ
    Curr Alzheimer Res; 2007 Sep; 4(4):427-36. PubMed ID: 17908047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin.
    Hashigucci K; Ogawa H; Ishidate T; Yamashita R; Kamiya H; Watanabe K; Hattori N; Sato T; Suzuki Y; Nagamine T; Aizawa C; Tamura S; Kurata T; Oya A
    Vaccine; 1996 Feb; 14(2):113-9. PubMed ID: 8852406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.